Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 16/01/2009, Revision: 54, Status: Authorised

What is established Stelara (ustekinumab) is a monoclonal antibody drug authorized in the European Union since 2009 for the treatment of several inflammatory diseases including moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis. It targets two immune system messenger molecules, interleukin 12 (IL-12) and interleukin 23 (IL-23),…